Abstracts Archive - Page 4 of 1683 - ATC Abstracts

2022 American Transplant Congress
The Role of Donor Sex in Females Undergoing Repeat Kidney Transplant: Does Prior Donor Sex Matter?
S. Craig¹, K. Tennankore², A. J. Vinson²
¹Dalhousie University, Halifax, NS, Canada, ²Nova Scotia Health Authority, Halifax, NS, Canada
*Purpose: Female recipients of male donor kidneys are at increased risk for graft failure compared with all other donor-recipient sex pairings. The presumed mechanism relates…
2022 American Transplant Congress
Decellularized Human Pancreatic Extracellular Matrix-Based Physiomimetic Microenvironment for Human Islet Culture
A. Asthana¹, D. Chaimov¹, R. Tamburrini², S. J. Walker³, G. Orlando¹
¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²University of Wisconsin Hospital and Clinics, Madison, WI, ³Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC
*Purpose: Maintenance of human islet viability and function ex vivo can be a significant bottleneck for both regenerative medicine as well as tissue engineering applications.…
2022 American Transplant Congress
Superoxide in Cardiac Allografts from Donors After Circulatory Death
M. Urban¹, T. Bruett², K. F. Duncan¹, N. W. Markin³, M. M. Chacon³, M. C. Zimmerman⁴
¹Department of Surgery. Division of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, ²College of Medicine. Department of Cellular and Integtrative Physiology., University of Nebraska Medical Center, Omaha, NE, ³Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE
*Purpose: Quality of cardiac allografts from donors after circulatory death (DCD) is adversely impacted by warm ischemia and subsequent reperfusion during organ resuscitation. Post-transplant myocardial…
2022 American Transplant Congress
HLA-II Subclasses Behave Differently Between Themselves and Between Humans: Cues to Understand Alloreactivity
S. Beland, O. Desy, M. Marcoux, M. Thivierge, J. Desgagnes, S. A. De Serres
Transplantation Unit, Renal Division, University Health Center of Quebec, Faculty of Medicine, Universite Laval, Quebec, QC, Canada
*Purpose: De novo anti-HLA-II DSAs (dnDSA) are associated with antibody-mediated rejection. However, some patients with anti-HLA-II DSAs will not develop rejection, suggesting that the development…
2022 American Transplant Congress
Deceased Donor Organ Flush with Similar Volumes of HTK and UW at a Single U.S. Organ Procurement Organization: Adult and Pediatric Data
A. E. Mangus¹, C. Kubal², B. Ekser³, P. Mihaylov⁴, A. J. Lutz¹, J. Fridell⁵, R. Mangus⁶
¹Indiana University Purdue University of Indianapolis, Indianapolis, IN, ²Indiana University Hospital, Indianapolis, IN, ³Surgery, Indiana University - Transplant Surgery, Indianapolis, IN, ⁴Indiana Univ School of Medicine, Indianapolis, IN, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶Indiana University, Indianapolis, IN
*Purpose: Histidine-tryptophan-ketoglutarate (HTK) and University of Wisconsin (UW) solutions are the two primary solid-organ preservation solutions used in the United States (>95%), but flush volumes…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…
2022 American Transplant Congress
COVID-19 Vaccination Induces a Poor Interleukin-21 Memory T-cell Response in Kidney Transplant Recipients
S. R. Malahe¹, Y. den Hartog¹, R. de Kuiper¹, D. Reijerkerk¹, D. Geers², C. H. GeurtsvanKessel², M. M. Kho¹, R. D. de Vries², M. E. Reinders¹, C. C. Baan¹
¹Internal Medicine, Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands, ²Viroscience, Erasmus MC, Rotterdam, Netherlands
*Purpose: COVID-19-related morbidity and mortality is high among kidney patients. Several studies recently suggested low humoral and cellular immune responses after two doses of mRNA-1273…
2022 American Transplant Congress
Single Cell RNAseq Analysis of Liver Transplant Rejection Reveals Highly Restricted TCR Clonal Expansion of Tissue-Resident Memory CD8⁺ T Cells That Persist Despite Corticosteroids and ATG Therapy
A. L. Peters¹, G. Begum¹, K. Roskin², E. Woodle³, D. Hildeman⁴
¹Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Bioinformatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Surgery, University of Cincinnati, Cincinnati, OH, ⁴Department of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Conventional therapy for liver transplant rejection (corticosteroids and ATG) has remained unchanged for six decades, and is not infrequently met with treatment failure. Here,…
2022 American Transplant Congress
Transplant Centers That Assess Frailty as Part of Clinical Practice Have Better Outcomes
X. Chen¹, Y. Liu¹, V. Thompson¹, N. M. Chu¹, E. A. King¹, J. D. Walston², J. A. Kobashigawa³, D. M. Dadhania⁴, D. L. Segev¹, M. A. McAdams-DeMarco¹
¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ³Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Nephrology and Hypertension, Weill Cornell Medicine, New York, NY
*Purpose: Frailty predicts adverse post-kidney transplant (KT) outcomes, yet impacts of frailty assessments on center-level outcomes remain unclear. We tested whether transplant centers assessing frailty…